Educational & Research Organizations

Led by Suresh Muthukumaraswamy, it runs controlled trials on LSD microdosing and psilocybin, including brain-imaging studies and mushroom drug-checking research.

UBC Department of Psychiatry lab conducting psychedelic-assisted therapy research including psilocybin for alcohol use disorder and programs for first responders, plus microdosing studies.

Founded 1998 by Amanda Feilding, it initiates and co-funds psychedelic research collaborations (Beckley/Imperial, Beckley/Sant Pau, Beckley/Maastricht) and advances drug-policy reform.

Led by Draulio de Araujo, it uses EEG and fMRI to study ayahuasca and psilocybin, and ran a landmark placebo-controlled trial of ayahuasca for treatment-resistant depression.

Founded 2022 in the College of Social Work, it conducts clinical trials and public-health research on underrepresented populations and offers a Certificate in Interdisciplinary Psychedelic Studies.

Launched 2021 at Harvard-affiliated MGH, studying how psychedelics affect cognition, emotion and the brain to improve treatment of depression, anxiety and PTSD.

Leading German center for psilocybin-assisted psychotherapy research, co-leading the EPIsoDE and DiMension trials and running one of Germany's first psilocybin compassionate-use programs.

Home to Australia's first psychedelic depression trial, running psilocybin, 5-MeO-DMT and IV psychedelic studies led by Professor Susan Rossell.

Founded in 2019 as the world's first formal psychedelic research centre, focused on the brain action and clinical use of psychedelics, notably psilocybin for depression, using modern brain imaging.

Founded 2020 by anthropologist Bia Labate, producing research and education bridging traditional plant-medicine use and psychedelic science, with a focus on culture, equity and Indigenous rights.

Founded 2015, it runs the first university-affiliated psychedelic-assisted therapy certificate program — having trained over 1,700 clinicians — plus new undergraduate and clinical programs.

Established 2020 in the Dept of Psychiatry — the first of its kind in Australia — running psychedelic therapy trials (psilocybin, MDMA, 5-MeO-DMT), therapist training, and mechanism research.

Globally recognized psychopharmacology group studying cognitive, behavioral and neurobiological effects of psychedelics (LSD, psilocybin, DMT) and MDMA, including microdosing paradigms.

Integrates psychiatry and spiritual health to study psychedelic-assisted psychotherapy, including the MOSAIC initiative on psychedelics and religious traditions.

An interdisciplinary hub spanning philosophy, psychology, anthropology and neuropharmacology of psychedelics, offering an MSc in Psychedelics: Mind, Medicine and Culture.

Leading continuing-education organization for psychedelic therapy, offering certificate programs in ketamine-, psilocybin- and MDMA-assisted therapy and harm reduction to thousands of clinicians.

Incorporated 1993, a virtual nonprofit that designs, reviews and funds leading psilocybin studies at major universities in the US and Europe.

Barcelona group founded by the late Jordi Riba that pioneered the first placebo-controlled human trials of ayahuasca and DMT, a foundational European psychedelic pharmacology program.

Launched in 2019 (the first such US center), it studies psychedelics such as psilocybin for treating depression, addiction, and other conditions, and to probe the nature of consciousness.

Matthias Liechti's group conducts leading human trials on the acute effects and pharmacology of LSD, psilocybin, DMT, mescaline and MDMA, and characterizes novel psychoactive substances.

Canada's first graduate program in psychedelic studies (launched 2024) — a Master's exploring therapeutic, spiritual and cultural uses of psychedelics with clinical and fieldwork components.

Cross-faculty network spanning social sciences, psychiatry and public health, coordinating research, policy and regulatory work on medicinal psychedelics in Australia and internationally.

Nonprofit advancing evidence-based psychedelic therapy through clinical trials (EPIsoDE, DiMension), the MIND Academy therapist training, the INSIGHT conference, and the UniMIND academic network.

Founded 1986 by Rick Doblin, the pioneering nonprofit funding and advancing psychedelic research (notably MDMA-assisted therapy for PTSD), education, and policy reform.

Contemplative-education center offering psychedelic-assisted therapy certificates, an undergraduate minor, and psilocybin facilitator training for the Oregon and Colorado regulated models.

Led by Gitte Moos Knudsen, the NRU uses PET and fMRI to study serotonin 2A receptor pharmacology and the brain effects of psilocybin and LSD, including cluster-headache trials.

Led by psychedelic pioneer Franz Vollenweider, it investigates molecular and neural mechanisms of psilocybin, LSD and entactogens on self, emotion and social cognition in health and disease.

NYU Langone center performing translational psychedelic research from preclinical work to Phase 3 trials for substance use, depression, PTSD, and cancer-related distress, with a research training program.

Founded 2007, the leading European nonprofit promoting interdisciplinary psychedelic research and education, and organizer of the biennial Interdisciplinary Conference on Psychedelic Research (ICPR).

Led by Rachel Yehuda, it runs clinical trials and neuroscience studies of MDMA and psilocybin for PTSD and trauma, plus therapist training and education.

University of Toronto Mississauga program establishing rigorous standards for psychedelic research, focused on microdosing of psilocybin and LSD and their effects on mood and cognition.

Charité psychiatry research group serving as the Berlin study center for the EPIsoDE psilocybin depression trial and studying recreational and psychedelic substances.

McGill units studying non-ordinary states of consciousness and the neurobiology of psychedelics (LSD, psilocybin, DMT), including large-scale mapping of psychedelic brain effects.

Opened 2023 at the Maudsley Hospital via a partnership with Compass Pathways and SLaM, running controlled trials of psilocybin, 5-MeO-DMT and MDMA for depression, PTSD and anorexia.

Housed in the School of Pharmacy, it runs Phase 1-3 psilocybin and MDMA trials and partners on the first accredited US master's degree in psychoactive pharmaceutical investigation.

Interdisciplinary UCSF program studying how psilocybin, LSD, MDMA and related compounds affect the brain, targeting mood disorders, substance use, movement disorders, and chronic pain.

Founded 2020 within the Helen Wills Neuroscience Institute, it spans basic science, applied research and policy, journalism, and public education, and runs a psychedelic facilitation certificate program.

UC San Diego School of Medicine center (formed 2023 from the Psychedelics and Health Research Initiative) conducting basic and clinical research on psychedelics for pain and other conditions.

Site of David Nutt's pioneering early psilocybin brain-imaging work and the founding of the Beckley collaboration, foundational to the modern UK psychedelic research field.

Nonprofit medical research organization (founded 2014) conducting preclinical and clinical research on psilocybin and related compounds, primarily for major depressive disorder.

Group led by Jaime Hallak, José Crippa and Rafael dos Santos conducting clinical and neuroscience research on ayahuasca and DMT for depression, anxiety and PTSD.

A Yale School of Medicine psychiatry program investigating psychedelic effects on mind and brain and their therapeutic potential, building on Yale's historic serotonin and LSD research.